DXB Chart, page-368

Plenty of upside remaining given the potential $Billion dollar market.

But, of course, its a punt on the binary outcome of the initial Phase 3 trial outcomes slated for mid-March.

If the outcomes are poor, its back to the sub-10's. If the outcomes are positive, its off to the races with 10-bagger plus potential from here, especially if additional markets are picked up.

How far and how fast it rises will be a product of the weight of sentiment as to the Trial outcome.

Plenty of clues as to which way it may go - ie. orphan drug status, Phase 2 positive outcome and especially the Advanz deal (with Advanz having full access to the data room).